Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Published byMartina Baldwin Modified over 6 years ago

Similar presentations

Presentation on theme: "Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,"— Presentation transcript:

1 Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial  James G. Krueger, MD, PhD, Laura K. Ferris, MD, Alan Menter, MD, Frank Wagner, MD, Alexander White, MD, Sudha Visvanathan, PhD, Bojan Lalovic, PhD, Stella Aslanyan, MD, Elaine E.L. Wang, MD, David Hall, PhD, Alan Solinger, MD, Steven Padula, MD, Paul Scholl, MB BChir  Journal of Allergy and Clinical Immunology  Volume 136, Issue 1, Pages e7 (July 2015) DOI: /j.jaci Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Mean PASI percentage improvement from baseline over 24 weeks. Mean improvements in PASI scores for patients receiving intravenous (IV) or subcutaneous (SC) BI are shown. For the intravenous BI group, there were 24 subjects to week 12 and 23 subjects thereafter; a patient originally allocated to the 5 mg/kg BI group was lost to follow-up because of relocation, and discontinued after week 12. For the BI subcutaneous group, there were 15 subjects throughout. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Representative photographs of PASI improvements with BI in a male (A) and female (B) patient from baseline (left panel) and week 12 (right panel). Fig 2, A, Single dose of 0.25 mg/kg BI administered subcutaneously. PASI scores were 39, 22, 9, 1.5, 0, and 0 at baseline and weeks 2, 4, 8, 12, and 24, respectively. Fig 2, B, Single dose of 1 mg/kg BI administered subcutaneously. PASI scores were 12.80, 9.5, 1.2, 1, 0.6, and 0 at baseline and weeks 2, 4, 8, 12, and 24, respectively. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Changes in expression of genes/proteins in key pathophysiologic pathways in psoriatic lesion development and maintenance after administration of a single dose of BI A, Representative skin biopsy specimens from a single patient treated with subcutaneous BI at a dose of 0.25 mg/kg (baseline and week 8) stained for specific markers, including K16 and Ki67, S100A7, neutrophil gelatinase lipocalin, β-defensin 2, DC-LAMP, CD11c, and CD3. B, Heat map showing FC expression (change from baseline to week 8) in a subset of 60 genes (significantly increased in lesional vs nonlesional skin) from a published RNA-seq analysis in patients with moderate-to-severe psoriasis15 that are overall normalized by treatment with BI (purple) versus placebo (green). The scale shows log2 FC in expression of each gene, with red representing FC increase and blue representing FC decrease. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 3 Changes in expression of genes/proteins in key pathophysiologic pathways in psoriatic lesion development and maintenance after administration of a single dose of BI A, Representative skin biopsy specimens from a single patient treated with subcutaneous BI at a dose of 0.25 mg/kg (baseline and week 8) stained for specific markers, including K16 and Ki67, S100A7, neutrophil gelatinase lipocalin, β-defensin 2, DC-LAMP, CD11c, and CD3. B, Heat map showing FC expression (change from baseline to week 8) in a subset of 60 genes (significantly increased in lesional vs nonlesional skin) from a published RNA-seq analysis in patients with moderate-to-severe psoriasis15 that are overall normalized by treatment with BI (purple) versus placebo (green). The scale shows log2 FC in expression of each gene, with red representing FC increase and blue representing FC decrease. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 4 Correlation plot of log FC in expression of IL-23/IL-17 axis–associated genes by means of RNA-seq versus TaqMan PCR after treatment with BI (adjusted for placebo response). RNA-seq and TaqMan PCR data calculated as follows: [logFC(BI treated (Week 8 − baseline)) − logFC(Placebo treated (Week 8 − Baseline))]. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E1 Patient disposition. aReasons for not meeting the inclusion criteria included viral hepatitis, other comorbidities, history of alcohol abuse, exclusionary laboratory results, inadequate response to prior biologics, or not meeting the age limit. bOne patient was originally randomized into the group receiving 1 mg/kg BI administered subcutaneously but received 0.25 mg/kg BI cPatient lost to follow-up because of relocation was originally allocated to the 5 mg/kg BI group and discontinued after week 12. dOne patient originally assigned to receive 1 mg/kg BI administered subcutaneously inadvertently received the 0.25 mg/kg dose. eOne patient was directly assigned to the group receiving 1 mg/kg BI administered subcutaneously to maintain 6 patients in the group. IV, Intravenous; SC, subcutaneous. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E2 BI dose response. Intravenous and subcutaneous bioavailability-normalized BI doses versus individual percentage change from baseline PASI score (AUEC). Data were calculated as described in the Results section in this article's Online Repository and depicted as black (intravenous [IV]) or gray (subcutaneous [SC]) triangles. A line of best fit of an Emax dose-response relationship (dashed line) is overlaid. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E3 Overall decrease in FC expression of a cluster of 79 genes using RNA-seq (baseline to week 8). Heat map showing overall decreases in FC expression (change from baseline to week 8) in a cluster of 79 genes from RNA-seq analysis after treatment with BI (purple) versus placebo (green), with each column representing individual patients. The scale shows log2 FCs in expression of each of the 79 genes, with red representing FC increase and blue representing FC decrease. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig E4 Correlation plot of the cluster means of the 79 genes (from Fig E1) for each patient versus PASI scores at week 8, showing a significant correlation between reductions in expression of this gene cluster in BI –treated patients and lower PASI scores (BI [purple dots] vs placebo [green dots]). The decrease in expression of this subset of 79 genes after BI treatment was significantly correlated with PASI scores at week 8 (r = 0.73, P = 2 × 10−6). Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,"

Similar presentations

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,

The effects of an anti–IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge  Grant C. Nicholson, BSc, Harsha H. Kariyawasam,
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer  Tali Czarnowicki, MD, Dana Malajian, BA, Saakshi Khattri, MD,

Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer  Tali Czarnowicki, MD, Dana Malajian, BA, Saakshi Khattri, MD,
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 
Theresa W. Guilbert, MD, David T. Mauger, PhD, David B

Theresa W. Guilbert, MD, David T. Mauger, PhD, David B
Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,
The importance of being “pure” neutrophils

The importance of being “pure” neutrophils
Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma  Anand C. Patel, MD, Mark L. Van Natta, MHS, James.
RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications  Mayte.

RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications  Mayte.
An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,
Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,

Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement  Shradha Agarwal, MD, Charlotte Cunningham-Rundles,
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Similar presentations

Ads by Google